Vor Biopharma Inc.

NASDAQ:VOR

Biotechnology

Healthcare
$17.83 -2.26%

-$0.34 today

Market cap
$966.13M
Beta
1.73
P/E (TTM)
-0.0
EPS (TTM)
-$2,053.13
52W Low $4.28High $65.80

Volume 0.79M

Average 1.07M

VOR Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Vor Biopharma Inc.NASDAQ: VOR

Weighted Avg Shares (Diluted) · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) dips below year-ago levels

Q1 FY2026 weighted avg shares (diluted) of 430.12K shares fell 93.1% year over year, behind the +40.8% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 95.6% from the prior quarter. Over 3 fiscal years it compounded at +70.9% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -93.1% toward the trailing-twelve-month pace of +40.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
430.12K-95.6% QoQ
Last fiscal yearDec 2025
9.87M+187.4% YoY
LTMMar 2026
5.81M+40.8% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-93.1%——
1 year+187.4%——
3-year CAGR+70.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
9.87M USD
Year-over-year change
+187.4%
4-year CAGR
+51.8%

Weighted Avg Shares (Diluted) vs competitors

How VOR compares with its peers on the latest reported figures

  • VOR's LTM Mar 2026 weighted avg shares (diluted) of 5.81M shares is the lowest of the 10 companies compared; the peer median is 110.2M shares.
  • Its year-over-year change of +40.8% is the highest of 10, against a peer median of +8.4%.
  • Over three fiscal years its annual growth of +70.9% compares with a peer median of +12.1%.
VOR Competitors Peer median
Weighted Avg Shares (Diluted) for VOR and competitors
Company Period LTM YoY 3-year CAGR
AUTLAutolus Therapeutics plcLTM Mar 2026266.14M +0.0%+41.0%
SANASana Biotechnology, Inc.LTM Mar 2026257.25M +9.0%+10.4%
FATEFate Therapeutics, Inc.LTM Mar 2026119.09M +1.0%+7.1%
RCKTRocket Pharmaceuticals, Inc.LTM Mar 2026111.46M +12.7%+17.7%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026110.2M +9.3%+12.1%
CRSPCRISPR Therapeutics AGLTM Sep 202694.81M +8.4%+5.0%
EDITEditas Medicine, Inc.LTM Mar 202690.28M +9.3%+8.9%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
NKTXNkarta, Inc.LTM Mar 202674.08M +0.6%+19.3%
VORVor Biopharma Inc.LTM Mar 20265.81M +40.8%+70.9%
Peer median (excluding VOR) 110.2M+8.4%+12.1%

Competitors are the stored peer set for VOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue08.96M3.49M00
Gross Profit0(8.96M)(3.49M)00
Gross Margin—————
Research & Development47.53M64.55M94.32M93.31M321.53M
Selling, General & Admin21.49M19.91M31.72M27.88M50.11M
Operating Expenses69.02M84.46M122.54M121.19M371.64M
Depreciation & Amortization1.43M8.96M3.49M3.53M2.89M
EBITDA(67.47M)(83.13M)(114.37M)(113.39M)(693.09M)
EBITDA Margin—————
Operating Income(69.02M)(93.42M)(126.04M)(121.19M)(371.64M)
Operating Margin—————
Interest Income119K1.32M8.17M4.27M5.87M
Interest Expense00000
Other Income / Expenses119K1.32M8.17M4.27M(324.34M)
Income Before Tax(68.9M)(92.09M)(117.86M)(116.91M)(695.98M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(68.9M)(92.09M)(117.86M)(116.91M)(695.98M)
Net Margin—————
EPS (Basic)(37.80)(46.60)(35.00)(34.00)(70.50)
EPS (Diluted)(37.80)(46.60)(35.00)(34.00)(70.50)
Weighted Avg Shares1.86M1.98M3.36M3.44M9.87M
Weighted Avg Shares (Diluted)1.86M1.98M3.36M3.44M9.87M

Vor Biopharma Inc.

NASDAQ:VOR

Intrinsic Alpha fair value

Locked

Current Price

$17.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.